Close Menu

New Products

Jul 31, 2020

Myriad Genetics Amplify for Fetal Cell-Free DNA Sequencing

Myriad Genetics has launched Amplify, which sequences the fetal cell-free DNA fragments circulating in a mother's blood and increases the fetal fraction in a sample for non-invasive prenatal screening. The company is hoping that the technology will improve the performance of its Prequel NIPS test. The analytical validation of Amplify involved samples from more than 1,000 women and showed that the fetal fraction was 2.3 times greater on average compared to standard NIPS. The improvement reduces false positive and false negative results, including for common aneuploidies, expanded aneuploidies, microdeletions, and a baby's sex, Myriad noted. The company also said that the technology will reduce the number of sampels that fail to produce a result due to low fetal fraction and deliver results to 99.9 percent of patients. 

Jul 29, 2020

HTG Molecular Diagnostics HTG EdgeSeq Pan B-Cell Lymphoma Panel

HTG Molecular Diagnostics has launched its HTG EdgeSeq Pan B-Cell Lymphoma Panel, which the firm said is designed to provide molecular characteriation of aggressive, indolent, and rare lymphomas. The research-use-only panel enables investigators to measure the expression of about 300 genes linked to the lymphoma transcriptome. The panel is available in kit form or as a service at HTG's VERI/O laboratory. 

Jul 28, 2020

Myriad Genetics: Vectra Report

Myriad Genetics has enhanced its test report for Vectra, a multi-biomarker, molecular blood test for measuring inflammatory disease activity in rheumatoid arthritis patients. The new report provides an estimate of each patient's one-year risk of rapid radiographic progression, factoring in age, gender, and adiposity. Previously, the company reported a measure of patients' current RA inflammation, but the added information in the latest version of the report can inform them of the future risk of joint damage and "further guide [their] medical management decisons," Mark Verratti, president of Myriad Neuroscience and Myriad Autoimmune, said in a statement. 

Jul 23, 2020

SphingoTec IB10 Sphingotest bio-ADM

SphingoTec launched IB10 Sphingotest bio-ADM, a CE IVD-marked point-of-care test to quantitatively determine blood levels of bioactive adrenomedullin. Blood levels of bio-ADM reflect the functional status of the endothelium, the inner cell sheet of blood vessels. The test is available on the company's rapid point-of-care platform Nexus IB10, which uses whole blood samples without pre-processing, requires less than three minutes of hands-on time, and delivers results in about 20 minutes.

Pages